{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:26:57Z","timestamp":1770434817548,"version":"3.49.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.crohns.2009.04.001","type":"journal-article","created":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T05:19:27Z","timestamp":1241327967000},"page":"212-214","source":"Crossref","is-referenced-by-count":19,"title":["Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease"],"prefix":"10.1093","volume":"3","author":[{"given":"Taxiarchis","family":"Felekis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Asproudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epameinondas V.","family":"Tsianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2009.04.001_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02339241","article-title":"Crohn's disease and multiple sclerosis: a single case report","volume":"15","author":"Buccino","year":"1994","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.crohns.2009.04.001_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00004836-199201000-00011","article-title":"Association of Crohn's disease and multiple sclerosis. Is there a common background?","volume":"14","author":"Purrmann","year":"1992","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.crohns.2009.04.001_bib3","article-title":"Tumor necrosis factor-alpha antibody for maintenance for remission in Crohn's disease (Review)","author":"Behm","year":"2008","journal-title":"Cochrane Collab"},{"key":"10.1016\/j.crohns.2009.04.001_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor \u03b1 therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.04.001_bib5","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w4","article-title":"Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease","volume":"140","author":"Strong","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2009.04.001_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.122.5.793","article-title":"Infliximab-associated retrobulbar optic neuritis","volume":"122","author":"Mejico","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.crohns.2009.04.001_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/bega.2002.0345","article-title":"Strategies for targeting tumour necrosis factor in IBD","volume":"17","author":"Sandborn","year":"2003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.04.001_bib8","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumour necrosis \u03b1 antagonism","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Supple 35","key":"10.1016\/j.crohns.2009.04.001_bib9","first-page":"134","article-title":"Demyelination and inhibition of tumour necrosis factor (TNF)","volume":"22","author":"Magnano","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.crohns.2009.04.001_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomised, placebo-controlled multicenter study","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.crohns.2009.04.001_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nn738","article-title":"TNFa promotes proliferation of oligodendrocyte progenitors and remyelination","volume":"4","author":"Arnett","year":"2001","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.crohns.2009.04.001_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11926-003-0005-9","article-title":"Lessons learned in the use of tumor necrosis factor \u03b1 inhibition in the treatment of rheumatoid arthritis","volume":"5","author":"Mikuls","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.crohns.2009.04.001_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1 neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.04.001_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ibd.20584","article-title":"Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease; a prospective single center study","volume":"15","author":"Felekis","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.04.001_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/135245850000600512","article-title":"Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases","volume":"6","author":"Constantinescu","year":"2000","journal-title":"Mult Scler"},{"key":"10.1016\/j.crohns.2009.04.001_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.crohns.2008.04.001","article-title":"Occurrence of demyelinating diseases after anti-TNFa treatment of inflammatory bowel disease: a Danish Crohn Colitis Database study","volume":"2","author":"Andersen","year":"2008","journal-title":"J Crohn Colitis"},{"key":"10.1016\/j.crohns.2009.04.001_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of Infliximab for the treatment of inflammatory bowel disease: a single center cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/3\/3\/212\/7799538\/3-3-212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T16:21:45Z","timestamp":1503418905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.04.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1873994609000282"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.04.001","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}